Summary In order to clarify the mechanism of drug resistance in human myeloma cells, we investigated the expressions of DNA topoisomerase I and topoisomerase II gene and the genes possibly related to drug resistance; multi‐drug resistant gene 1 (MDR‐1), glutathione S‐transferase class π gene (GST‐π), by Northern blotting. Myeloma cells in eight of 15 cases prior to chemotherapy expressed topoisomerase I mRNA considerably, while the expression of topoisomerase II mRNA was detected weakly in only one of 16 myeloma patients. There was not any correlation between expression of topoisomerase I mRNA and clinical drug resistance. Significant expression of MDR‐1 mRNA and P‐glycoprotein was not detected in 25 cases of multiple myeloma prior to chemotherapy and even after several courses of VAD (vincristine, adriamycin and dexamethasone) therapy by Northern blotting and immunostaining using monoclonal anti‐P‐glycoprotein antibody (MRK‐16), respectively. On the other hand, 16 of 21 myeloma cases showed significant expression of GST‐π protein and GST‐π mRNA with the various strengths, but there was no apparent correlation between GST‐π mRNA expression and clinical response. Therefore these data suggest that expression of the genes we tested may not determine the level of drug resistance in multiple myeloma, but lower or no significant expression of topoisomerase II mRNA in most myeloma cells indicates the possibility that topoisomerase II inhibitors such as VP‐16 and topoisomerase II‐mediated cytotoxic drugs such as adriamycin, are not so effective for the treatment of multiple myeloma.
|Number of pages||7|
|Journal||British Journal of Haematology|
|Publication status||Published - 1993 Jan|
ASJC Scopus subject areas